AC
ARDS

Armistice Capital’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Armistice Capital’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,068,000
Closed -$2.44M – 264
2022
Q4 		$2.44M Buy
+2,068,000
New +$2M 0.04% 112
2021
Q4 		– Sell
-1,068,444
Closed -$3.93M – 185
2021
Q3 		$3.93M Buy
+1,068,444
New +$4.94M 0.07% 111

Other funds holding ARDS

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Armistice Capital's ARDS Position: Q1 2023 in Review

Armistice Capital sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q1 2023, closing a stake of 2,068,000 shares — an estimated $2.44M sold.

Armistice Capital first reported a position in ARDS in Q3 2021 and held it in 2 quarters. The position peaked at $3.93M in Q3 2021. 20 funds tracked by Wall St. Rank hold ARDS as of Q1 2023.

  • Armistice Capital reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Armistice Capital sold 2,068,000 Aridis Pharmaceuticals Inc. Common Stock shares in Q1 2023, an estimated $2.44M.
  • Armistice Capital first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Armistice Capital's Aridis Pharmaceuticals Inc. Common Stock position peaked at $3.93M in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.